Driving Breakthroughs in Type 1 Diabetes
A decade of support for Breakthrough T1D’s mission to find new treatments, prevention, and cures for type 1 diabetes (T1D).
Their support has helped position Breakthrough T1D at the forefront of T1D research, driving projects with life-changing potential, such as cell therapies which hold the potential to cure T1D by replacing the insulin-producing beta cells destroyed by the immune system.
In 2024, Breakthrough T1D launched Project ACT, an initiative designed to bring cell therapies to people with T1D faster. Project ACT addresses all stages of the development pipeline, from advancing research, influencing regulatory pathways, ensuring coverage and access, and preparing healthcare systems for clinical readiness. Combined with new disease-fighting treatments that work to stop the body’s immune system from attacking those insulin-producing cells, these efforts could finally make T1D a thing of the past.
As Breakthrough T1D’s CEO Aaron Kowalski affirms: “As steadfast supporters of our mission, Igor and Anastasia share our vision to make T1D a condition of the past. Their partnership drives our mission forward by advancing groundbreaking research and innovative treatments that change the lives of so many in the T1D community.”
Anastasia and Igor’s philanthropic work in this area now continues under the Bukhman Foundation, reflecting their commitment to empowering individuals with T1D and pursuing a future free from the condition.
About Breakthrough T1D
Breakthrough T1D is a global leader in research and advocacy for type 1 diabetes (T1D), dedicated to enhancing the lives of those living with the condition while working towards prevention and cures. The organisation invests in cutting-edge research, collaborates with government and industry partners to improve access to care, and provides resources to empower individuals and families. By breaking barriers and driving innovation, Breakthrough T1D is transforming the future for the T1D community.